Research progress in proprotein convertase subtilisin/kexin type 9 monoclonal antibody
10.3760/cma.j.issn.1674-635X.2016.03.011
- VernacularTitle:前蛋白转化酶枯草溶菌素9单克隆抗体研究进展
- Author:
Yinghao SUN
;
Naishi LI
;
Weigang ZHAO
- Publication Type:Journal Article
- Keywords:
Proprotein convertase subtilisin/kexin type 9;
Monoclonal antibody;
Dyslipidemia;
Evo-locumab;
Alirocumab;
Bococizumab
- From:
Chinese Journal of Clinical Nutrition
2016;24(3):172-178
- CountryChina
- Language:Chinese
-
Abstract:
Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an important role in lipid reg-ulation through interaction with low-density lipoprotein cholesterol receptors , and several types of PCSK 9 inhibi-tors are gradually becoming research hotspots due to their lipid lowering effect .Among them PCSK9 monoclonal antibodies are the closest to clinical application , and a number of phase Ⅲclinical trials in PCSK9 monoclonal antibodies have been completed in recent years .We systemically reviewed the current clinical research on PC-SK9 monoclonal antibodies in this paper , in order to understand their efficacy and long-term safety in reducing the risk of cardiovascular diseases .
